SAN DIEGO, CA, Sept. 15, 2020 – Multimeric Biotherapeutics, Inc. (“Multimeric” or the “Company”), a biotechnology company developing immunotherapies and vaccines against infectious diseases and cancer, today announced that the U.S. Patent and Trademark Office has issued Patent No. 10/774/149 B2, entitled “Composition Comprised of Antigen Linked to a TNF Superfamily Ligand.” Joint inventors are Geoffrey W. Stone and Richard S. Kornbluth.
Continue ReadingNews
Multimeric Biotherapeutics, Inc. Announces Issuance of a European Patent for FortiVac™ – a Vaccine Design That Elicits Strong CD8+ T Cell Responses for Anti-Viral Immunity and Tumor Immunotherapy
SAN DIEGO, CA, Dec. 25, 2019 – Multimeric Biotherapeutics, Inc. (“Multimeric” or the “Company”), a biotechnology company developing immunotherapies and vaccines against infectious diseases and cancer, today announced that the European Patent Office (EPO) has issued Patent No. EP 2 970 427 B1, entitled “Composition Comprised of Antigen Linked to a TNF Superfamily Ligand.” Joint inventors are Geoffrey W. Stone and Richard S. Kornbluth.
Continue ReadingMultimeric Biotherapeutics, Inc. Announces Issuance of Key US Patent for FortiVacTM – a Vaccine Design That Elicits Strong CD8+ T Cell Responses for Anti-Viral Immunity and Tumor Immunotherapy
SAN DIEGO, CA, Sept. 11, 2018 – Multimeric Biotherapeutics, Inc. (“Multimeric” or the “Company”), a biotechnology company developing immunotherapies and vaccines against infectious diseases and cancer, today announced that the U.S. Patent and Trademark Office has issued Patent No. 10,072,064, entitled “Composition Comprised of Antigen Linked to a TNF Superfamily Ligand.” Joint inventors are Geoffrey W. Stone and Richard S. Kornbluth.
Continue Reading